CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics' stock price has experienced fluctuations in the past six months. The stock has increased significantly over the last 12 months, but decreased in the month leading up to March 30, 2026. Positive Phase 1 Varseta-M data led to a surge in the stock price. CytomX announced a public offering of common stock and pre-funded warrants. The company reported a decrease in 2025 total revenue compared to 2024, and a collaboration deal with Bristol-Myers Squibb ended, with Astellas also terminating preclinical research programs.

There is no specific information available regarding demand seasonality for CytomX Therapeutics, Inc.'s products or services. Demand for its future products would primarily be driven by the prevalence of the targeted cancers and the efficacy and safety profile of its treatments.

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing masked, conditionally activated biologics for cancer treatment using its Probody® therapeutic platform. This platform creates antibody-based drugs that are inactive until they reach the tumor microenvironment, minimizing activity in healthy tissues. The company's pipeline includes Varseta-M (CX-2051), CX-904, CX-801, CX-2029, and BMS-986288. CytomX has strategic partnerships with companies like Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna.

CytomX Therapeutics, Inc. is headquartered in South San Francisco, California, United States. The company's stock is traded on the NasdaqGS in the United States, and also on the Stuttgart, Frankfurt, Dusseldorf, and Berne Stock Exchanges in Europe.

CytomX Therapeutics generally has a positive brand reputation, with a consensus rating of "Moderate Buy" from analysts. Positive clinical trial data and successful enrollment expansion have boosted confidence in the company. However, a decline in cash and investments, collaboration terminations, and insider selling could negatively affect its reputation.

The ownership structure of CytomX Therapeutics (CTMX) stock includes institutional, retail, and individual investors. Institutional investors own a significant portion of the company's stock, while insiders hold a smaller percentage. Major institutional owners include Fmr Llc, VR Adviser, LLC, and Perceptive Advisors Llc. Joseph Edelman owns the most shares among individual investors, and the company's CEO, Sean McCarthy, directly holds a portion of the total shares outstanding.